Good news! It is expected that 100 Chinese medicines will be promoted nationally.

Medicine Network October 15th, the state will recommend the unique efficacy of Chinese medicine species recently, the State Administration of Traditional Chinese Medicine to the provinces (districts, cities) of the Chinese Medicine Administration issued "on the recommendation of Chinese medicine treatment advantages of diseases, appropriate technology and unique efficacy of Chinese medicine species notice."
notification requirements, the provinces (districts, cities) recommended the advantages of diseases, appropriate technology, Chinese medicine species are not more than 5 kinds, and before October 20, 2020 to report the recommendation form, and then the State Administration of Traditional Chinese Medicine will hire relevant experts to set up a review expert group, the recommended Chinese medicine species and other content to review, and form a list to promote to the community.
The recommended Chinese medicine species refers to chinese medicines that have been approved for market, excluding Chinese medicine tablets and medical institutions, and the clinical positioning, functional treatment, adaptive, applicable population, usage, course of treatment, adverse reactions and precautions of Chinese medicine species with unique efficacy should be accurate and clear.
according to the previous relevant documents, the list of recommended varieties will be controlled within 100, if according to a single province recommended Chinese medicine species are 5 calculations, the total recommended varieties are expected to be about 150.
, about two-thirds of the recommended varieties at the provincial level have a good chance of entering the recommended queue of the State Administration of Traditional Chinese Medicine.
the expected 100 Chinese medicine species or good notice shows that the recommendation is mainly to implement the "CPC Central Committee, the State Council on promoting the heritage and innovation of Chinese medicine" deployment of the relevant tasks.
According to the Cypress Blue Inquiry, last year issued by the State Council of the CPC Central Committee on promoting the innovation and development of Chinese medicine heritage, clearly mentioned that highlighting the advantages of Chinese medicine in the treatment of diseases, as well as vigorously promoting the quality of Chinese medicine and high-quality industrial development advice requires accelerating the construction of Chinese medicine evidence-based medical center, with about 3 years time, screening 50 Chinese medicine treatment advantages and 100 suitable technologies, 100 unique efficacy of Chinese medicine, timely release to the community.
(National Bureau of Traditional Chinese Medicine, National Health And Health Commission, Ministry of Science and Technology responsible for) opinion 18 pointed out that focusing on cancer, cardiovascular disease, diabetes, infectious diseases, Alzheimer's disease and antibiotic resistance issues, to carry out the joint research of Chinese and Western medicine, by 2022 to form and promote 50 or so Chinese and Western medicine combined treatment programs. Article 46 of the
Opinion points out that exploring the establishment of clinical value-oriented evaluation path, comprehensive use of evidence-based medicine and other methods, increase the efforts of post-market evaluation of traditional Chinese medicines, establish a linkage mechanism with public hospital drug procurement, basic drug selection, medical insurance catalog adjustment, etc., to promote industrial upgrading and structural adjustment.
(The State Drug Administration, the State Health Insurance Administration, the National Health And Health Commission, the State Administration of Traditional Chinese Medicine are responsible for each) for the recommended Chinese medicine species, if the drug procurement, base drug selection, medical insurance catalog adjustment and other aspects of the tilt, is undoubtedly a good.
provinces and cities are carrying out the recommendation work according to the incomplete statistics of Cypress Blue, so far, Jiangsu, Jilin, Shaanxi, Beijing, Hebei and other provinces and cities have issued relevant notices on the recommendation of Chinese medicine species.
Jiangsu requires no more than 5 kinds of Chinese medicines to be recommended, each unit has submitted a recommendation form by October 13, Jilin also requires no more than 5 kinds of Chinese medicines recommended, and the recommendation form will be reported by October 14th, which is also before today, and Shaanxi Province requires 1 By October 15th, the recommendation form will be called to the Science and Technology and Industry Department of the Shaanxi Provincial Administration of Traditional Chinese Medicine, and Hebei requires that Chinese medicines be declared by enterprises within the jurisdiction of the municipal notification, and each enterprise shall recommend no more than one, and each unit shall report the recommendation form to the Hebei Provincial Administration of Traditional Chinese Medicine by October 19th.
Recently, the Beijing Municipal Administration of Traditional Chinese Medicine issued the Notice on the Organization of the Declaration of Chinese Medicine Types with Advantages of Chinese Medicine Treatment, Appropriate Technology and Unique Efficacy, and the requirements for the reporting of Chinese medicine species in Beijing are as follows: 1. The central government in Beijing public secondary and above Chinese medicine (including the combination of Chinese and Western medicine, ethnic medicine, the same below) medical institutions, Beijing Force public secondary and above medical institutions (2 projects per limited); 2. Beijing is a public secondary and above Chinese medicine medical institutions (2 projects per limited to report); 3. Chinese medicine enterprises registered in the Beijing area with independent legal personality, Sino-foreign joint ventures shall be controlled by the Chinese side (1 project per limited report).
filings should be expected by 18:00 on 16 October.
varieties will be selected? Recently, with the support of the Chinese Pharmaceutical Society, the Report on the Scientific and Technological Competitiveness of Chinese Medicine Varieties, led by the Chinese Medicine Variety Alliance, selected 579 Chinese medicine varieties from the three dimensions of "clinical value, scientific value and market value" among the 59,595 Chinese medicine products currently on the market.
The chinese medicine varieties here are different from the traditional sales as the basis for judging large varieties, which refers to the varieties with significant or exact clinical efficacy, meet clinical needs, high scientific and technological content, distinctive characteristics of Chinese medicine, and have a large market share.
From the selection basis, here the Chinese medicine varieties shortlisted standards and the State Administration of Traditional Chinese Medicine put forward a unique efficacy and other requirements are still somewhat similar, how many of these 579 large varieties of Chinese medicine can enter the list of national recommended Chinese medicine species, and get national recommendations, it is worth looking forward to.
, it is well known that there is a certain fragmentation between the development of Chinese medicine at the level of policy support and hospital use.
Although high-level policies to support the development of Traditional Chinese medicine have been introduced many times, the adjustment of the medical insurance catalogue and the base medicine catalogue has also sent a signal of support for Chinese medicine, and with the increase in per capita income level, as well as the increase in the incidence of chronic diseases have provided opportunities for the development of traditional Chinese medicine.
But the provincial focus on monitoring the drug system has brought pressure on the clinical use of Chinese medicine, in addition, the hospital side of the rational use of various drugs policies are affecting the use of Chinese medicine in the hospital, many more than 1 billion Chinese medicine sales continued to decline.
the relevant departments directly from the Chinese medicine level to release the signal to support Chinese medicine, whether the relevant varieties will bring good market opportunities, whether it will further promote the development of the Chinese medicine industry, it remains to be seen.
.